##common.search##
##search.searchResults##
-
THE IMPORTANCE OF MORPHOLOGICAL FORMS OF ECHINOCOCCAL CYSTS ON THE FREQUENCY OF RECURRENCE OF THE DISEASE
To determine the effect of the morphological form of echinococcal cysts on the incidence of recurrence of the disease, we conducted a retrospective analysis of the operation protocols and determined that in 93 (36.9%) operated patients, the morphological structure of the cysts corresponded to modifications of echinococcus hominis, 128 (50.8%) - echinococcus veterinorum and in 31 (12.3%) - echinococcus acephalocystis. Moreover, in 47 patients with developed recurrence of the disease, 29 (61.7%) had morphological signs corresponding to echinococcus hominis, 18 (38.3%) had echinococcus veterinorum, and no recurrence was detected in those operated on with the morphological structure of the corresponding echinococcus acephalocystis. Thus, out of 93 patients operated on for liver echinococcosis with a morphological structure corresponding to the form of echinococcus hominis, 29, i.e. in 31.2%, a relapse of the disease was observed, out of 128 operated on with morphological modification of echinococcus veterinorum cysts in 18, i.e. 14.1% also developed recurrent echinococcosis in the long term after the operation.
-
MEASURES TO PREVENT RECURRENCE AFTER SURGICAL TREATMENT OF LIVER ECHINOCOCCOSIS
The clinical study included 371 patients with liver echinococcosis. Optimization of the tactics of surgical treatment of liver echinococcosis, taking into account the choice of access, method of treatment and elimination of the residual cavity, as well as correction of the course of prophylactic chemotherapy, improved the quality of care by reducing the frequency of immediate postoperative complications from 12.5% to 4.3% and the recurrence of the disease from 11.9% to 2.6%. It is clinically justified to correct the dose of albendazole for the prevention of recurrence of liver echinococcosis in patients with concomitant chronic diffuse liver pathology, which made it possible to reduce the likelihood of adverse reactions from 52.7% to 18.3%, and, accordingly, indicators of hepatic aminotransferases: ALT in the comparison group from 1.14± 0.11 to 0.62±0.05 mmol/l in the main group and AST from 0.72±0.07 to 0.52±0.04 mmol/l.